AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25240461
Drug: ω‐3 PUFAs-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFAs-containing fish oil (average DHA and EPA doses of 72.9 and 117.1 mg/kg b.w./day) for 12 months
Trial: 23133592
Drug: Choline intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline intake of 480 mg/day
Trial: 23133592
Drug: Choline intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline intake of 930 mg/day
Trial: 8556698
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone and insulin-like growth factor 1 treatment
Trial: 29056418
Drug: Dexmedetomidine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (25 μg kg−1)
Trial: 29056418
Drug: Dexmedetomidine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (25 μg kg−1) with MK‐467 (600 μg kg−1)
Trial: 26037292
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg loading dose before PCI
Trial: 26037292
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg loading dose at the time of PCI
Trial: 15365929
Drug: 0.5% bupivacaine/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine/1.5 microg/kg of fentanyl with 5 microg/mL of epinephrine (group IPBF)
Trial: 15365929
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with 5 microg/mL of epinephrine (group IPB)
Trial: 15365929
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (group IVF)
Trial: 25885964
Drug: LISA (less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LISA (less invasive surfactant administration) group, n=47
Trial: 24497658
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia and Pain (CBT-PI)
Trial: 21098740
Drug: Bortezomib-dexamethasone induction
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib-dexamethasone induction therapy
Trial: 19179299
Drug: Valsartan (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (oral suspension, 2 mg/kg, max 80 mg)
Trial: 11351143
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg o.a.d.
Trial: 26973167
Drug: Cortisol administration
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol administration 40 min before extinction memory retrieval
Trial: 26973167
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration 40 min before extinction memory retrieval
Trial: 20844543
Drug: Efonidipine-based regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efonidipine-based regimen in strict-treatment group (target systolic BP <140 mm Hg)
Trial: 20844543
Drug: Efonidipine-based regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efonidipine-based regimen in mild-treatment group (target systolic BP 140 to <160 mm Hg)
Trial: 20844543
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with baseline eGFR <60 ml min⁻¹ per 1.73 m²
Trial: 20844543
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with baseline eGFR ≥60 ml min⁻¹ per 1.73 m²
Trial: 17715031
Drug: Esmolol (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (loading dose of 0.5 mg/kg in 30 ml normal saline over 5 min followed by an infusion of 50 microg.kg(‐1).min(‐1) until the end of surgery)
Trial: 16042670
Drug: Erythromycin 1200
RxNorm normalized name: ERYTHROMYCIN 1200 mg in 30 g TOPICAL GEL [Spotex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1200 mg day(‐1) for 7 days
Trial: 1761737
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil single doses of 100, 200, 400, 600, and 800 mg
Trial: 1761737
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil multiple doses of 100, 200, and 400 mg twice daily for 15 days
Trial: 1761737
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (both single and multiple doses)
Trial: 12364422
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride at 60 mg/d (group A)
Trial: 12364422
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet/d; group B)
Trial: 9868651
Drug: 1 mg/(kg.d)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/(kg.d) liposomal amphotericin B (L‐AmB‐1)
Trial: 9868651
Drug: 4 mg/(kg.d)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/(kg.d) liposomal amphotericin B (L‐AmB‐4)
Trial: 3293408
Drug: Hygienic informational
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygienic informational therapy
Trial: 3293408
Drug: Nondrug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondrug therapy (blood pressure responders)
Trial: 3293408
Drug: Hygienic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygienic therapy
Trial: 25423327
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide 800 mg daily
Trial: 25423327
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide 1200 mg daily
Trial: 18663663
Drug: Serological biomarkers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological biomarkers (pepsinogen I, pepsinogen II, gastrin-17, Helicobacter pylori antibodies)
Trial: 12658930
Drug: Trimetazidine plus
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine plus routine therapy
Trial: 12443576
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy only
Trial: 2346354
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of rifamycin SV
Trial: 2346354
Drug: Iodinated polyvidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodinated polyvidone dermal solution
Trial: 400108
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol (100 microgram four times daily)
Trial: 20618675
Drug: Chair‐type training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chair‐type training machine for the elderly, 60‐min sessions twice a week for 12 weeks
Trial: 18363672
Drug: Weight-based ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.5 microg/kg/week
Trial: 18363672
Drug: Weight-based ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.0 microg/kg/week
Trial: 18363672
Drug: PEG-IFN alfa-2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Trial: 12451365
Drug: Alefacept 7.5
RxNorm normalized name: ALEFACEPT 7.5MG/VI INJ KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept 7.5 mg
Trial: 7547094
Drug: tenidap 120
RxNorm normalized name: tenidap
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tenidap 120 mg day-1
Trial: 7195230
Drug: AR-L 115
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-L 115 BS, 0.7 mg/kg
Trial: 7195230
Drug: Dobutamine, 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine, 0.01 mg/kg
Trial: 30921340
Drug: DNA prime
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA prime (ADVAX) and Modified Vaccine Ankara (MVA) boost
Trial: 28660370
Drug: Coverage restrictions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coverage restrictions in prescription drug plans
Trial: 28660370
Drug: Formulary generosity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulary generosity in prescription drug plans
Trial: 25063041
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 2.7 g per day for 2 weeks
Trial: 21849055
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care in combination with the particular tape technique
Trial: 18611341
Drug: 1,208 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,208 mmol/L (9%) KCl infusion
Trial: 18611341
Drug: 201 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 201 mmol/L (1.5%) potassium chloride infusion
Trial: 7652501
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g 8-hourly)
Trial: 7652501
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g 8-hourly)
Trial: 1978026
Drug: IgG3 monoclonal
RxNorm normalized name: Anti-Gd2 igg3 monoclonal antibody 3F8 humanized
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IgG3 monoclonal antibody
Trial: 1978026
Drug: IgG1 monoclonal
RxNorm normalized name: Human anti-CD94 IgG1 monoclonal antibody (non-fucosylated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG1 monoclonal antibody
Trial: 31682266
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral CBD
Trial: 31682266
Drug: Vaporized CBD-dominant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized CBD-dominant cannabis (100 mg CBD; 3.7 mg ∆9-THC)
Trial: 17201801
Drug: Replacement-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement-dose recombinant methionyl human leptin (r-metHuLeptin) during 72-hour fasting
Trial: 17201801
Drug: 72-hour fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72-hour fasting (without leptin administration)
Trial: 11880017
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg
Trial: 11226112
Drug: Saline 2
RxNorm normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 2 mL
Trial: 3276279
Drug: Methyldopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500 mg/d)
Trial: 3276279
Drug: Oxprenolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (80 mg/d)
Trial: 18482454
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg elemental iron (as ferrous fumarate) multivitamin
Trial: 18482454
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg elemental iron (as ferrous sulphate) multivitamin
Trial: 16169655
Drug: Dentin-bonding agent
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentin-bonding agent
Trial: 11113718
Drug: Atenolol (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (maintenance dose 89±11 mg/day, range 50-100 mg/day)
Trial: 8474401
Drug: Amitriptyline oxide
RxNorm normalized name: amitriptyline oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline oxide (60 mg)
Trial: 6743780
Drug: Trimipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine (50 mg)
Trial: 3776446
Drug: Intramuscular oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular oxycodone on request following an intraoperative intercostal block (Group C)
Trial: 3776446
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine as a continuous infusion of 0.25% bupivacaine (Group EB)
Trial: 3776446
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4 mg injected prior to surgery and on the first postoperative morning (Group EM4)
Trial: 3776446
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 6 mg injected prior to surgery and on the first postoperative morning (Group EM6)
Trial: 29529169
Drug: SOC +
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOC + AAP (abiraterone acetate 1000 mg + prednisolone 5 mg daily)
Trial: 29529169
Drug: SOC +
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOC + DocP (docetaxel 75 mg/m2 3-weekly x 6 + prednisolone 10 mg daily)
Trial: 19875232
Drug: Pain Clinic
RxNorm normalized name: Stopain Clinical
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Clinic treatment
Trial: 18160741
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone antagonist plus testosterone administration for 4 weeks
Trial: 16177164
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide treatment (NO); N2O and EMLA
Trial: 16177164
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CO); cutaneous application of EMLA
Trial: 16177164
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide treatment (NO)
Trial: 16177164
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide treatment (NO) and Conventional treatment (CO)
Trial: 12709682
Drug: Diltiazem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (1 g/kg/min during CPB)
Trial: 11128561
Drug: Teicoplanin 400
RxNorm normalized name: Teicoplanin 400 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 400 mg/day i.m. for a minimum of 4 months
Trial: 11128561
Drug: Teicoplanin 200
RxNorm normalized name: Teicoplanin 200 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 200 mg/day i.m. (reduced dose for 2 patients)
Trial: 11128561
Drug: Teicoplanin treatment
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin treatment
Trial: 6388897
Drug: Neomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin (2 g/day)
Trial: 6388897
Drug: Neomycin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin plus Niacin (3 g/day)
Trial: 6388897
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with Neomycin plus Niacin
Trial: 6388897
Drug: Diet-only therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet-only therapy
Trial: 31402718
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (NAPSO) 440 mg
Trial: 26573022
Drug: Ceftobiprole 500
RxNorm normalized name: ceftobiprole medocaril sodium 667 MG (equivalent to ceftobiprole 500 MG) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftobiprole 500 mg, administered by 2-hour intravenous infusion every 8 hours.
Trial: 27129122
Drug: PRTX-100 (0.15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRTX-100 (0.15, 0.45, 0.90, or 1.50 µg/kg)
Trial: 22959335
Drug: Reduced-intensity conditioning
RxNorm normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-intensity conditioning (4 doses of 2 Gy total-body irradiation and 150 mg/m² fludarabine)
Trial: 22959335
Drug: Standard conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conditioning (6 doses of 2 Gy total-body irradiation and 120 mg/kg cyclophosphamide)
Trial: 18156036
Drug: COX-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COX-2 inhibitors (rofecoxib, celecoxib, sulindac, meloxicam, indometacin) with low-dose aspirin
Trial: 18156036
Drug: COX-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COX-2 inhibitors with low-dose aspirin
Trial: 18156036
Drug: COX-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COX-2 inhibitors (celecoxib, rofecoxib) with low-dose aspirin
Trial: 18156036
Drug: Non-selective NSAIDs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective NSAIDs with low-dose aspirin
Trial: 15074088
Drug: Imitate preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imitate preparation in control group
Trial: 16098301
Drug: Dobutamine stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine stress echocardiography with real-time low mechanical index perfusion imaging (using intravenous Optison)
Trial: 8743516
Drug: Ca antagonists
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca antagonists
Trial: 1656826
Drug: Intravenous foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous foscarnet at a dose of 60 mg/kg body weight three times a day for 3 weeks followed by 90 mg/kg once a day (treatment group)
Trial: 1656826
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (delayed treatment, control group)
Trial: 1656826
Drug: Intravenous foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous foscarnet treatment
Trial: 1656826
Drug: Foscarnet treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet treatment
Trial: 30951586
Drug: Home-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based behavioral skills treatment
Trial: 20810101
Drug: Maintenance antidepressants
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance antidepressants (mADM)
Trial: 15757007
Drug: Inpatient relapse
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient relapse prevention (RP) program (treatment goal met)
Trial: 15757007
Drug: Inpatient relapse
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient relapse prevention (RP) program (treatment goal not met)
Trial: 7541435
Drug: Propacetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (2 g every 6 hr)
Trial: 31299655
Drug: Tiopronin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin (3 g daily for up to 14 days after aSAH)
Trial: 25904586
Drug: Particle-filtered air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particle-filtered air (PM2.5 levels of 3 µg/m(3))
Trial: 25904586
Drug: Sham-filtered air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-filtered air (PM2.5 levels of 24 µg/m(3))
Trial: 12027853
Drug: Bicarbonate infusion
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate infusion
Trial: 23552179
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (in subset with baseline creatinine clearance < 60 mL/min)
Trial: 23552179
Drug: Bicarbonate infusion
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate infusion (in subset with baseline creatinine clearance < 60 mL/min)
Trial: 17265545
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi training (18 weeks, 45 min, twice a week)
Trial: 16100235
Drug: GIK (glucose-insulin-potassium)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK (glucose-insulin-potassium) treatment
Trial: 16100235
Drug: GIK treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK treatment